Evidence map›Paper›PMID 41403841›Full record

ArticleiScience2025

Safety and immunogenicity of DNA omicron booster Alveavax-v1.2 in Ad26.COV2.S-vaccinated adults.

Maximilian Schons, Tobias Odendahl, James A Smith, Kyle Fish, Anemone Franz, Miti Saksena, Sonia Sutherland, Vaughan Reed, Phumzile Mhlongo, Madeli Kruger and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Maximilian SchonsAlvea LLC, Cambridge, MA, USA.
Tobias OdendahlAlvea LLC, Cambridge, MA, USA.
James A SmithAlvea LLC, Cambridge, MA, USA.
Kyle FishAlvea LLC, Cambridge, MA, USA.
Anemone FranzAlvea LLC, Cambridge, MA, USA.
Miti SaksenaAlvea LLC, Cambridge, MA, USA.
Sonia SutherlandMicron Research, Ely, Cambridgeshire, UK.
Vaughan ReedMicron Research, Ely, Cambridgeshire, UK.
Phumzile MhlongoUbuntu Clinical Research, Lenasia, Johannesburg, South Africa.
Madeli KrugerUbuntu Clinical Research, Lenasia, Johannesburg, South Africa.
Zinhle ZwaneSetshaba Research Centre, Soshanguve, Pretoria, South Africa.
Kgoete DimakatsoSetshaba Research Centre, Soshanguve, Pretoria, South Africa.
Carol CrowtherAIRU, Sandrigham, Johannesburg, South Africa.
Penny MooreUniversity of the Witwatersrand, Sandringham, Johannesburg, South Africa.
Veronique De JagerTASK Brooklyn, Stanberry Street, Brooklyn, Cape Town, South Africa.
Ethan AlleyAlvea LLC, Cambridge, MA, USA.
Grigory KhimulyaAlvea LLC, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A phase I study assessed the safety and immunogenicity of the naked DNA Omicron BA.2 booster vaccine, Alveavax-v1.2, in 130 South African adults previously vaccinated with Janssen Ad26.COV2.S. Participants received varying doses intradermally or subcutaneously, or a Janssen booster as a control. The vaccine was well tolerated, with mild to moderate adverse events across all groups and no serious events linked to vaccination. However, the antibody response was modest, with no significant increases in Omicron BA.2 titers observed in any group. The vaccine remained shelf stable for over six months at room temperature.

Indexed as

ImmunologyMedicine;Medical specialtyRealth sciences

Identifiers

PMID41403841
PMCPMC12704268

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.